melanoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
This melanogenic function of UVRAG is controlled by the melanocyte-specific transcription factor MITF as a downstream effector of the α-melanocyte-stimulating hormone (α-MSH)-cAMP signaling in the suntan response, which is compromised in BRAF mutant melanoma.
|
30209981 |
2019 |
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Radiolabeled α-melanocyte-stimulating hormone (α-MSH) derivatives have a high potential for diagnosis and treatment of melanoma, because of high specificity and binding affinity to the melanocortin-1 receptor (MC1R).
|
30912594 |
2019 |
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Herein, we sought to establish a simple preparation method for an <sup>18</sup>F-labeled α-MSH analog using Al<sup>18</sup>F, and we examined its potential for the early detection of melanoma.
|
31297699 |
2019 |
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
This may be a reason for concern in patients with malignant melanoma (MM): Melanocortin receptors bind to ACTH and the different isoforms of MSH.
|
31272482 |
2019 |
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
αMSH peptide sequences, evaluated for conjugation to the PEG-Cy5-C' dot nanoparticles, bound to MC1-R with high affinity and targeted melanoma in syngenetic and xenografted melanoma mouse models.
|
29058865 |
2018 |
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
In this study, we aim to design and evaluate αMSH derivatives that enable radiolabeling with <sup>18</sup>F for PET imaging of melanoma.
|
29714486 |
2018 |
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
These results highlight the potential of using radiolabeled αMSH analogues in clinical applications for molecular imaging and radionuclide therapy of melanoma.
|
29182034 |
2018 |
melanoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
MC1R, a G-protein coupled receptor with high affinity for alpha-melanocyte stimulating hormone (αMSH), modulates pigment production in melanocytes from many species and is associated with human melanoma risk.
|
29316344 |
2018 |
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Radionuclide Targeting: α-Melanocyte-stimulating hormone (α-MSH) is the most prominent peptide for targeting of melanoma tumors via the G protein-coupled melanocortin-1 receptor that is (over-)expressed by melanoma cells and melanocytes.
|
28578648 |
2017 |
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
[Leu<sup>3</sup>, Leu<sup>7</sup>, Phe<sup>8</sup>]-γ-MSH-NH<sub>2</sub> is ideal for inducing short-term skin pigmentation without sun for melanoma prevention.
|
29094944 |
2017 |
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Linear and cyclic analogues of the α-melanocyte stimulating hormone (α-MSH) targeting the human melanocortin receptor 1 (MC1R) are of pharmacological interest for detecting and treating melanoma.
|
28714883 |
2017 |
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Radiolabeled linear or cyclic analogs of α-MSH have a great potential as diagnostic or therapeutic tools for the management of malignant melanoma.
|
28491052 |
2017 |
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
We previously identified the αMSH/Peroxisome Proliferator Activated Receptor (PPARγ) pathway as a new pathway on the B16-F10 mouse melanoma cell line.
|
29020973 |
2017 |
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Alpha melanocyte stimulating hormone (α-MSH) enhances melanogenesis in melanoma malignum by binding to melanocortin-1 receptors (MC1-R).
|
28625749 |
2017 |
melanoma
|
0.400 |
Therapeutic
|
disease |
CTD_human |
Because the apoptotic cells were detected mainly in regions distant from blood vessels, it was hypothesized that POMC therapy might render melanoma cells vulnerable to hypoxic insult.
|
24412703 |
2014 |
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The importance of the MC1R in reducing UV-induced genotoxicity in melanocytes led us to design small peptide analogs of the physiological MC1R agonist α-melanocortin (α-melanocyte stimulating hormone; α-MSH) for the goal of utilizing them for melanoma chemoprevention.
|
25017567 |
2014 |
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Together, these results indicate that HDGF downregulation participates in POMC-induced suppression of metastasis and EMT in melanoma.
|
23468531 |
2013 |
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Linking αMSH with PPARγ in B16-F10 melanoma.
|
22863076 |
2013 |
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Our previous studies have indicated that POMC gene delivery inhibited the progression and metastasis of B16-F10 melanoma via the α- melanocyte-stimulating hormone/melanortin-1 receptor (MC-1R) pathway.
|
22147647 |
2012 |
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
In summary, systemic POMC therapy suppresses melanoma growth via induction of melanogenic differentiation and angiogenesis blockade, thereby demonstrating its potential as a novel treatment modality for melanoma.
|
21126174 |
2011 |
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Wnt/β-catenin signaling is stimulated by α-melanocyte-stimulating hormone in melanoma and melanocyte cells: implication in cell differentiation.
|
21040502 |
2011 |
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Furthermore, the relevance of alpha-melanocyte-stimulating hormone-mediated signaling for the induction of cytotoxicity was assessed in CD8(+) T cells from melanoma patients with functional and nonfunctional melanocortin-1 receptors.
|
20126537 |
2010 |
melanoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Syndecan-2 expression was enhanced by fibroblast growth factor-2, which is known to stimulate melanoma cell migration; however, alpha-melanocyte-stimulating hormone decreased syndecan-2 expression and melanoma cell migration and invasion in a melanin synthesis-independent manner.
|
19641225 |
2009 |
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
An (18)F-labeled linear alpha-MSH peptide ((18)F-FB-Ac-Nle-Asp-His-d-Phe-Arg-Trp-Gly-Lys-NH(2) [NAPamide]) shows promising melanoma imaging properties but with only moderate tumor uptake and retention.
|
19837749 |
2009 |
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
In melanocytes and melanoma cells alpha-melanocyte stimulating hormone (alpha-MSH), via the cAMP pathway, elicits a large array of biological responses that control melanocyte differentiation and influence melanoma development or susceptibility.
|
15983061 |
2005 |